reports
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence...
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU - Only ~20% of individuals with genetic variants linked to ADH1 were found to have an es...
BridgeBio to Host Second Quarter 2025 Financial Results Conference Cal...
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webc...
BridgeBio Raises $300 Million Through Partial Capped Monetization of B...
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio’s European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45xIn the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM ...
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor W...
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund wi...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
RMAX RE/MAX HOLDINGS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LOCO EL POLLO LOCO HOLDINGS INC
DIN DINE BRANDS GLOBAL INC.
MSGS MADISON SQUARE GARDEN SPORTS CORP. CLASS A
TCI TRANSCONTINENTAL REALTY INVESTORS INC
RDFN REDFIN CORPORATION
NANX NANOPHASE TECHNOLOGIES CORP.
BH BIGLARI HOLDINGS B
PAYS PAYSIGN INC
BBIO BRIDGEBIO PHARMA
VIAC VIACOMCBS INC. CLASS B
HIMS HIMS AND HERS HEALTH INC (A)
OSCR OSCAR HEALTH
LMND LEMONADE INC
ASTS AST SPACEMOBILE INC
SRM SRM ENTERTAINMENT INC
LGCY LEGACY EDUCATION INC.
BATRA LIBERTY MEDIA CORPORATION
OXOTECH OXO TECHNOLOGIES HLDG PLC
PHH PARK HA BIOLOGICAL TECHNOLOGY CO. LTD.
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healt...
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET. To access the live webcast of BridgeBio’s presentation during the fireside chat, please visit the “Events...
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients...
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients: - In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo-...
Early and Sustained Increase in Serum TTR Levels by Acoramidis Indepen...
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes - ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May...
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever A...
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM - ACT-EARLY is a registrational, randomized, double blind, placebo controlled, event driven prevention study that will enroll ~600 asymptomatic carriers of a pathogenic TTR variant...
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and I...
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin a...
BridgeBio to Participate in the Bank of America Merrill Lynch Global H...
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within t...
BridgeBio Reports First Quarter 2025 Financial Results and Business Up...
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing receptor antagonist, in hypoparathyroidism resulted in 78% of N=9 study participants achieving co...
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%)...
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM - The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month ...
BridgeBio to Host First Quarter 2025 Financial Results Conference Call...
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webca...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 20 new employees in restricted stock units for an aggregate of 77,652 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will ves...
Acoramidis Shows Statistically Significant Improvements in Cardiovascu...
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysisThis profound treatment effect, due to the near-complete stabilization (≥90%) and binding of TTR, represents the greatest observed benefit to date for ATTRv-CM patients, an ATTR-CM population with poor prognosis In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%)...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably sepa...
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Var...
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 10 new employees in restricted stock units for an aggregate of 30,782 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will ve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.